Please login to the form below

Not currently logged in
Email:
Password:

fluticasone furoate

This page shows the latest fluticasone furoate news and features for those working in and with pharma, biotech and healthcare.

GSK gets maintenance indication for Trelegy

GSK gets maintenance indication for Trelegy

The new US label means Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) can be used in a broader population of chronic obstructive pulmonary disease (COPD) patients with difficulty breathing or who see ... GSK claims Trelegy has made the

Latest news

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    on LABA vilanterol, LAMA  umeclidinium and ICS fluticasone furoate - in the US and Europe last year. ... salmeterol and fluticasone propionate) that was a $7bn product at its peak but has seen sales slip of late, coming in at $3.3bn in the first nine

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    The EU regulator cleared Trelegy (fluticasone furoate/umeclidinium/vilanterol) - considered to be the most important new product in the company’s ailing respiratory franchise - as a maintenance treatment in adults with ... GSK has been bringing other

  • CDC backs GSK’s Shingrix over Merck & Co’s Zostavax CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

    That helped offset continued declines for GSK’s past-its-prime asthma and chronic obstructive pulmonary disease (COPD) therapy Advair/Seretide (fluticasone propionate/salmeterol), which saw sales decline 7% to ... Nucala itself saw sales more than

  • With US approval, GSK now needs rapid uptake for COPD triple With US approval, GSK now needs rapid uptake for COPD triple

    The FDA approved Trelegy (fluticasone furoate/umeclidinium/vilanterol) for the long-term, once-daily maintenance treatment of COPD patients who suffer breakthrough exacerbations despite being treated with two-drug combinations. ... Specifically, Trelegy

  • GSK closes in on EU approval for triple COPD therapy GSK closes in on EU approval for triple COPD therapy

    The EMA's advisory committee gave its blessing for Trelegy/Elebrato (fluticasone furoate, umeclidinium and vilanterol) as a maintenance therapy for COPD patients who do not respond to two-drug therapy ... product, now facing sales declines because of

More from news
Approximately 5 fully matching, plus 34 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics